News
1 September 2020
Cambridge Cognition secures three late phase schizophrenia trials
Cambridge Cognition is pleased to announce that it has won a £2m contract as the cognitive assessment partner for three late phase clinical trials for a pharmaceutical company's lead drug candidate for patients with schizophrenia. It is one of the largest single contracts secured by the Company and the revenue from the contract should be booked over the next four years with the majority recognised in 2021.
Read on
15 July 2020
New virtual study to measure stress recovery in frontline health workers caring for COVID-19 patients
Cambridge Cognition is pleased to announce a collaboration with 4YouandMe and The Center for International Emergency Medical Services to investigate the utility of wearables and mobile phones for measuring stress recovery in frontline health workers caring for COVID-19 positive patients.
Read on
30 June 2020
Cambridge Cognition announces further contract wins in the first half of 2020
Further contract wins in the first half of 2020 takes the Company's order intake to £4.9m for the year to date.
Read on
27 May 2020
CANTAB Research Grant 2020 - Results
The results of the 2020 CANTAB Research Grant are in! Once again we were overwhelmed by the quality of applications we received – which made it a tough job for our judging panel to narrow the research proposals down.
Read on
27 May 2020
Cambridge Cognition wins increasing numbers of virtual clinical trials during COVID-19
Cambridge Cognition is pleased to announce that the Company has recently won several new contracts to support pharmaceutical clients in delivering virtual clinical trials, including two contracts collectively worth over £1 million.
Read on
17 March 2020
Cambridge Cognition wins £1.37m of new eCOA contracts
The Company is pleased to announce that it has won a contract for three phase II studies with a new pharmaceutical client - providing CANTABTM cognitive assessments and eCOA services.
